Fund Manager Summary on EchoIQ Ltd (ASX:EIQ)
In March 2026, Wilson Asset Management commented that EchoIQ Ltd (ASX:EIQ) had strengthened its outlook after an expanded resale and distribution agreement with Mayo Clinic for EchoSolv HF, which they said validated the product, reduced FDA pathway risk, and could help unlock further US market expansion and early revenue generation. Overall, fund manager commentary on EchoIQ has become progressively more constructive, with Cadence Capital in June 2025 noting strong share-price performance after FDA approval for the company’s technology and an integration agreement with Beth Israel Deaconess Medical Centre, while also taking profits and later re-entering via the capital raise, and Wilson Asset Management in February and March 2026 highlighting the market opportunity in heart failure, the importance of FDA clearance and clinical validation, and the potential for strategic partnerships and additional hospital signings. The consensus view is that EchoIQ’s core opportunity lies in its AI-driven cardiology software, particularly as regulatory approvals, clinical validation, and institutional partnerships improve credibility and expand the US addressable market, but the key risks remain execution on FDA milestones, commercial adoption at scale, and the need to convert strategic interest into durable revenue and reimbursement gains.
Commentary From The Managers
There are 5 insights from 2 fund managers regarding their investment in EchoIQ Ltd (ASX:EIQ) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Investment Ideas Scanner
Elders Ltd (ASX:ELD): Rain-driven cattle rebound and Delta acquisition catalyst
Clime backs Straker (ASX:STG) after 13% rally - FY25 results preview
Spark New Zealand (ASX:SPK): Why managers added it back on valuation and dividend potential
Robex Resources (ASX:RXR): Kiniero ramp-up and PDI merger to drive 400kozpa by 2029
Why fund managers back Motio (ASX:MXO) — on track for $2.5–3m FY26 EBITDA
Dec 2025: Why WAM backs Lowell Resources Fund (ASX:LRT) — 91% gain, ~20% NAV discount
Why fund managers are selling Nuix after CEO exit (ASX:NXL)
Indiana Resources (ASX:IDA) — 5cps capital return drove 114% distributions
Fund managers on West African Resources ASX:WAF — Kiaka first pour, 500koz pa & 30% FCF
TWE undervalued: Penfolds strength, China rebound and buyback catalyst
Frequently Asked Questions
Who is investing in EchoIQ Ltd (ASX:EIQ)?
Fund managers including Cadence Capital and Wilson Asset Management have invested in EchoIQ Ltd (ASX:EIQ).
Why do fund managers invest in EchoIQ Ltd?
Fund managers have invested in EchoIQ because it is an Australian medical technology company with proprietary AI software for cardiology. Investor commentary points to FDA approval for severe aortic stenosis and progress on heart failure detection as key drivers. They also cite clinical validation and distribution agreements with the Mayo Clinic and Beth Israel Deaconess Medical Centre, which may support US market expansion. The investment case reflects growth potential, but it remains a high-risk, event-driven opportunity.
What happened to EchoIQ Ltd (ASX:EIQ)?
There have been no recent updates from fund managers regarding EchoIQ Ltd although fund managers including Cadence Capital have previously commented.
What is the short interest in EchoIQ Ltd (ASX:EIQ)?
The short interest in EchoIQ Ltd (ASX:EIQ) is 0.01% which makes it the 521st most shorted stock on the ASX. Of the 650.3M shares that EchoIQ Ltd has on issue, 80.1K have been sold short.
What does EchoIQ Ltd (ASX:EIQ) do?
EchoIQ Ltd. engages in the development and application of artificial intelligence for the cardiac diagnostics sector, as well as the supply of software used by the health fund and insurance sector. It operates through the Houston WeHave Software and Echo IQ segments. The Houston WeHave Software segment offers products and services across defence and other sectors. The Echo IQ segment focuses on developing artificial intelligence software that aids in predicting Aortic Stenosis heart condition. The company was founded by Richard Charles Anstey on March 31, 2010 and is headquartered in Sydney, Australia.